Cargando…
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review
Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the American College of Cardiology Foundation. Published by Elsevier.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963001/ https://www.ncbi.nlm.nih.gov/pubmed/33741176 http://dx.doi.org/10.1016/j.jacc.2021.02.035 |
_version_ | 1783665558798991360 |
---|---|
author | Talasaz, Azita H. Sadeghipour, Parham Kakavand, Hessam Aghakouchakzadeh, Maryam Kordzadeh-Kermani, Elaheh Van Tassell, Benjamin W. Gheymati, Azin Ariannejad, Hamid Hosseini, Seyed Hossein Jamalkhani, Sepehr Sholzberg, Michelle Monreal, Manuel Jimenez, David Piazza, Gregory Parikh, Sahil A. Kirtane, Ajay J. Eikelboom, John W. Connors, Jean M. Hunt, Beverley J. Konstantinides, Stavros V. Cushman, Mary Weitz, Jeffrey I. Stone, Gregg W. Krumholz, Harlan M. Lip, Gregory Y.H. Goldhaber, Samuel Z. Bikdeli, Behnood |
author_facet | Talasaz, Azita H. Sadeghipour, Parham Kakavand, Hessam Aghakouchakzadeh, Maryam Kordzadeh-Kermani, Elaheh Van Tassell, Benjamin W. Gheymati, Azin Ariannejad, Hamid Hosseini, Seyed Hossein Jamalkhani, Sepehr Sholzberg, Michelle Monreal, Manuel Jimenez, David Piazza, Gregory Parikh, Sahil A. Kirtane, Ajay J. Eikelboom, John W. Connors, Jean M. Hunt, Beverley J. Konstantinides, Stavros V. Cushman, Mary Weitz, Jeffrey I. Stone, Gregg W. Krumholz, Harlan M. Lip, Gregory Y.H. Goldhaber, Samuel Z. Bikdeli, Behnood |
author_sort | Talasaz, Azita H. |
collection | PubMed |
description | Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs. |
format | Online Article Text |
id | pubmed-7963001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | by the American College of Cardiology Foundation. Published by Elsevier. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79630012021-03-17 Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review Talasaz, Azita H. Sadeghipour, Parham Kakavand, Hessam Aghakouchakzadeh, Maryam Kordzadeh-Kermani, Elaheh Van Tassell, Benjamin W. Gheymati, Azin Ariannejad, Hamid Hosseini, Seyed Hossein Jamalkhani, Sepehr Sholzberg, Michelle Monreal, Manuel Jimenez, David Piazza, Gregory Parikh, Sahil A. Kirtane, Ajay J. Eikelboom, John W. Connors, Jean M. Hunt, Beverley J. Konstantinides, Stavros V. Cushman, Mary Weitz, Jeffrey I. Stone, Gregg W. Krumholz, Harlan M. Lip, Gregory Y.H. Goldhaber, Samuel Z. Bikdeli, Behnood J Am Coll Cardiol The Present and Future Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs. by the American College of Cardiology Foundation. Published by Elsevier. 2021-04-20 2021-03-16 /pmc/articles/PMC7963001/ /pubmed/33741176 http://dx.doi.org/10.1016/j.jacc.2021.02.035 Text en © 2021 by the American College of Cardiology Foundation. Published by Elsevier. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | The Present and Future Talasaz, Azita H. Sadeghipour, Parham Kakavand, Hessam Aghakouchakzadeh, Maryam Kordzadeh-Kermani, Elaheh Van Tassell, Benjamin W. Gheymati, Azin Ariannejad, Hamid Hosseini, Seyed Hossein Jamalkhani, Sepehr Sholzberg, Michelle Monreal, Manuel Jimenez, David Piazza, Gregory Parikh, Sahil A. Kirtane, Ajay J. Eikelboom, John W. Connors, Jean M. Hunt, Beverley J. Konstantinides, Stavros V. Cushman, Mary Weitz, Jeffrey I. Stone, Gregg W. Krumholz, Harlan M. Lip, Gregory Y.H. Goldhaber, Samuel Z. Bikdeli, Behnood Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review |
title | Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review |
title_full | Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review |
title_fullStr | Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review |
title_full_unstemmed | Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review |
title_short | Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review |
title_sort | recent randomized trials of antithrombotic therapy for patients with covid-19: jacc state-of-the-art review |
topic | The Present and Future |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963001/ https://www.ncbi.nlm.nih.gov/pubmed/33741176 http://dx.doi.org/10.1016/j.jacc.2021.02.035 |
work_keys_str_mv | AT talasazazitah recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT sadeghipourparham recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT kakavandhessam recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT aghakouchakzadehmaryam recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT kordzadehkermanielaheh recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT vantassellbenjaminw recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT gheymatiazin recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT ariannejadhamid recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT hosseiniseyedhossein recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT jamalkhanisepehr recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT sholzbergmichelle recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT monrealmanuel recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT jimenezdavid recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT piazzagregory recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT parikhsahila recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT kirtaneajayj recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT eikelboomjohnw recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT connorsjeanm recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT huntbeverleyj recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT konstantinidesstavrosv recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT cushmanmary recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT weitzjeffreyi recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT stonegreggw recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT krumholzharlanm recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT lipgregoryyh recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT goldhabersamuelz recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview AT bikdelibehnood recentrandomizedtrialsofantithrombotictherapyforpatientswithcovid19jaccstateoftheartreview |